BIAF
NASDAQ · Biotechnology
Bioaffinity Technologies Inc
$3.87
+0.33 (+9.32%)
Open$3.50
Previous Close$3.54
Day High$4.09
Day Low$3.40
52W High$46.53
52W Low$0.69
Volume—
Avg Volume48.72M
Market Cap21.32M
P/E Ratio—
EPS$-15.42
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+633.6% upside
Current
$3.87
$3.87
Target
$28.39
$28.39
$22.24
$28.39 avg
$33.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 19.09M | 608.9K | 644.1K |
| Net Income | -46,181,840 | -195,635 | -204,930 |
| Profit Margin | -242.0% | -32.1% | -31.8% |
| EBITDA | -32,614,625 | -176,028 | -183,952 |
| Free Cash Flow | — | -119,784 | -113,422 |
| Rev Growth | — | +18.5% | +20.2% |
| Debt/Equity | 0.11 | 1.28 | 1.08 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |